Protein-Functionalized Microgel for Multiple Myeloma Cells’ 3D Culture
Biomedicines, 2022 Multiple myeloma is a hematologic neoplasm caused by an uncontrolled clonal proliferation of neoplastic plasma cells (nPCs) in the bone marrow. The development and survival of this disease is tightly related to the bone marrow environment.
Juan Carlos Marín-Payá +5 more
doaj +1 more source
Asian Journal of Medical Sciences, 2014 Chronic myeloid leukemia (CML) is a haematopoietic neoplasm with clinically distinct phases and BCR⁄ABL1 oncogene. Imatinib mesylate, a potent inhibitor of BCR-ABL was highly effective in CML but later in-vitro derived cell line with resistance namely ...
Rajat Rana
doaj +1 more source
Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
Frontiers in Pharmacology, 2021 Multiple myeloma (MM) is a plasma cells neoplasm. The overexpression of Bcl-2 family proteins, particularly myeloid cell leukemia 1 (Mcl-1), plays a critical role in the pathogenesis of MM.
Omar S. Al-Odat +12 more
doaj +1 more source
Repurposing drugs to target nonalcoholic steatohepatitis [PDF]
, 2019 Nonalcoholic fatty liver disease (NAFLD) is a complex disorder that has evolved in recent years as the leading global cause of chronic liver damage.
Pirola, Carlos José +1 more
core +1 more source
Imatinib-induced interstitial pneumonitis – a literature review and case report [PDF]
, 2020 Imatinib is generally well tolerated, with mild common side effects such as nausea and vomiting, diarrhea, muscle cramps, fatigue, skin rash and edema; however, pulmonary complications are uncommon. A 73-year-old woman undergoing one month treatment with
Ciulei, George +12 more
core +2 more sources
Efficacy of adalimumab as second-line therapy in a pediatric cohort of crohn’s disease patients who failed infliximab therapy: The Italian society of pediatric gastroenterology, hepatology, and nutrition experience [PDF]
, 2019 Background: Adalimumab (Ada) treatment is an available option for pediatric Crohn’s disease (CD) and the published experience as rescue therapy is limited.
Accomando S. +15 more
core +1 more source
Essential procedures of single-cell RNA sequencing in multiple myeloma and its translational value
Blood Science, 2023 Multiple myeloma (MM) is a malignant neoplasm characterized by clonal proliferation of abnormal plasma cells. In many countries, it ranks as the second most prevalent malignant neoplasm of the hematopoietic system.
Jun Du +4 more
doaj +1 more source
Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia [PDF]
, 2014 Chronic myeloid leukemia (CML) is a stem cell (SC) neoplasm characterized by the BCR/ABL1 oncogene. Although mechanisms of BCR/ABL1-induced transformation are well-defined, little is known about effector-molecules contributing to malignant expansion and ...
Bilban, Martin +15 more
core +1 more source
A case of rhinoscleroma treated with ciprofloxacin [PDF]
, 2001 Respiratory scleroma (often termed \'rhinoscleroma\') is a chronic inflammatory condition in which deforming masses of tissue distend the nasal cavity. Klebsiella rhinoscleromatis is the causative agent of this infection and the Mikulicz cell is specific
Badia, L, Lund, VJ
core +1 more source
Frontiers in Pharmacology, 2022 Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, driven by the BCR-ABL1 fusion oncoprotein. The discovery of orthosteric BCR-ABL1 tyrosine kinase inhibitors (TKIs) targeting its active ATP-binding pocket, such as first-generation Imatinib
Hao Zhang +10 more
doaj +1 more source